Celldex Therapeutics Inc. (NASDAQ:CLDX) was the target of a significant increase in short interest in the month of November. As of November 15th, there was short interest totalling 22,319,708 shares, an increase of 9.0% from the October 31st total of 20,470,656 shares. Currently, 22.3% of the company’s shares are short sold. Based on an average daily trading volume, of 3,718,806 shares, the short-interest ratio is currently 6.0 days.
Several hedge funds have recently added to or reduced their stakes in CLDX. Veritable L.P. purchased a new stake in Celldex Therapeutics during the second quarter worth approximately $132,000. Virginia Retirement Systems ET AL purchased a new stake in Celldex Therapeutics during the third quarter worth approximately $150,000. AMP Capital Investors Ltd purchased a new stake in Celldex Therapeutics during the third quarter worth approximately $177,000. Bank of Montreal Can purchased a new stake in Celldex Therapeutics during the second quarter worth approximately $188,000. Finally, BlackRock Advisors LLC increased its stake in Celldex Therapeutics by 12.2% in the third quarter. BlackRock Advisors LLC now owns 52,107 shares of the biopharmaceutical company’s stock worth $211,000 after buying an additional 5,683 shares during the last quarter. Institutional investors and hedge funds own 76.21% of the company’s stock.
Shares of Celldex Therapeutics (NASDAQ:CLDX) opened at 4.43 on Friday. The firm’s market capitalization is $448.53 million. The firm has a 50-day moving average price of $3.78 and a 200-day moving average price of $4.09. Celldex Therapeutics has a 1-year low of $2.85 and a 1-year high of $18.56.
Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings data on Monday, November 7th. The biopharmaceutical company reported ($0.29) EPS for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.04. The business earned $2.20 million during the quarter, compared to the consensus estimate of $1.09 million. Celldex Therapeutics had a negative return on equity of 51.46% and a negative net margin of 1,923.41%. The business’s revenue for the quarter was up 115.5% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.32) EPS. On average, analysts forecast that Celldex Therapeutics will post ($1.29) EPS for the current fiscal year.
CLDX has been the subject of several research analyst reports. Roth Capital restated a “buy” rating and set a $7.00 price target on shares of Celldex Therapeutics in a research report on Thursday, November 10th. Cantor Fitzgerald restated a “buy” rating and set a $9.00 price target on shares of Celldex Therapeutics in a research report on Tuesday, November 8th. Zacks Investment Research upgraded Celldex Therapeutics from a “hold” rating to a “buy” rating and set a $5.00 price target for the company in a research report on Thursday, November 17th. Wedbush restated a “neutral” rating and set a $3.00 price target on shares of Celldex Therapeutics in a research report on Tuesday, November 8th. Finally, Brean Capital assumed coverage on Celldex Therapeutics in a research report on Tuesday, October 4th. They set a “buy” rating and a $16.00 price target for the company. Six investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Celldex Therapeutics presently has an average rating of “Buy” and a consensus target price of $7.44.
About Celldex Therapeutics